METHODS A group of 8 experts on the management of schizophrenia and LAIs met to
evaluate the evidence and to develop a set of recommendations regarding the clinical use …

Nonadherence with medication occurs in all chronic medical disorders. It is a particular
challenge in schizophrenia due to the illness's association with social isolation, stigma, and …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Objective: Data on the effectiveness of antipsychotics in the early phase of schizophrenia
are limited. The authors examined the risk of rehospitalization and drug discontinuation in a …

Despite their widespread use, long-acting injectable (LAI) antipsychotics (APs) are often
regarded with some negativity because of the assumption of punishment, control and …

Schizophrenia is a debilitating chronic disease that requires lifelong medical care and
supervision. Even with treatment, the majority of patients relapse within 5 years, and suicide …

The paper presents the use of the difference GMM and the system GMM for the purpose of
determining the critical determinants of non-performing loans. The aim of the paper is to …

Background The burden associated with schizophrenia is substantial. Impacts on the
individual, healthcare system, and society may be particularly striking within the veteran …

Introduction Understanding patients' preferences for long-acting injectable (LAI) or oral
antipsychotics (pills) could help reduce potential barriers to LAI use in schizophrenia …

Schizophrenia and related disorders remain major disabling conditions, mainly due to
antipsychotic treatment resistance and to relapses related to antipsychotic nonadherence …